Vaccines and Global Health: The Week in Review
25 February 2023 :: Issue 692
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Milestones, Perspectives

"Pandemic Treaty"

Fourth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response
27 February – 3 March 2023  10:00–13:00 and 14:30–17:30 CET, Geneva, Switzerland
- A/INB/4/1 Provisional agenda
- A/INB/4/3 Zero draft of the WHO CA+ for the consideration of the Intergovernmental Negotiating Body at its fourth meeting
- Webcast here

... At this meeting, the INB will consider the Zero Draft of the instrument, developed by the Bureau of the INB following widespread consultation, and is expected to confirm whether the Zero Draft will be the basis of negotiations for a pandemic accord during INB4, and if so, to initiate an in-depth chapter-by-chapter discussion of the document.

It is proposed that the discussion of the Zero Draft start at the INB4 and continue during the fifth meeting of the INB, to be held on 3-6 April 2023. The INB will report on the process of the development of the Accord to the 76th World Health Assembly in May 2023.

During the first day of INB4, the INB will begin consideration of the Zero Draft as part of a plenary meeting, held in open session during a “first reading”. This "first reading" will be open to WHO Member States, Associate Members and regional economic integration organizations, as well all relevant stakeholders (as agreed by the INB, set out in document A/INB/3/5). It is expected that the INB will invite relevant stakeholders to provide their views on the Zero Draft during the first day of the meeting. In line with the ways of working (“Method of Work”) (A/INB/1/3 Rev. 1) agreed by the Member States at the first INB and decisions at the third meeting of the INB, the INB will then continue its consideration of the Zero Draft in a “drafting group”, with attendance limited to: WHO Member States, Associate Members, regional economic integration organizations, and the observer delegations of the Holy See and Palestine.

The plenary of INB4 meeting will be webcast on the WHO website from this page and archived for later viewing. A procedural report will be discussed on the last day (in a plenary meeting, which will be webcast) and subsequently posted on the governing bodies section of the WHO website.

IHR (2005)

Governments hold first detailed discussions on proposed amendments to the International Health Regulations (2005)
25 February 2023  Statement
Governments agreed on a way forward for updating the WHO International Health Regulations 2005 (IHR), holding the first round of intensive discussions on more than 300 amendments proposed by countries to this globally agreed instrument. The IHR set out agreed approaches and obligations for countries to prepare for, and respond to, disease outbreaks and other acute public health risks. The proposed amendments come in response to the challenges posed by the COVID-19 pandemic.

The Second meeting of the Working Group on Amendments to the International Health Regulations (2005) took place from 20-24 February, during which the proposed amendments were discussed for the first time. The Group heard the intent behind the 307 amendments proposed by governments and shared views on each. They also agreed on next steps to tackle more in-depth negotiations on the proposed amendments, and plans for its next meeting on 17-20 April.

Co-Chair of the IHR Working Group, Dr Ashley Bloomfield, said ...“COVID-19 showed us that having a good, strong set of International Health Regulations is essential, and showed where the current Regulations need to be improved...The ongoing pandemic has underscored the importance of countries working together collaboratively, and supporting WHO in its vital work, to make the world safer. The tone of the discussions and progress made during this week’s meeting clearly show that countries understand the responsibility they have to ensure this process is successful.”

Throughout the week-long meeting, the 194 Member States of WHO, who are also State Parties to the IHR, stressed the importance of enhancing capacity building, especially in low-income countries; access to benefits arising from sharing pathogens; equitable access to medical countermeasures; and enhanced cooperation and information sharing...

In the lead-up to the meeting, an independent and diverse team of experts prepared a technical assessment of the proposed amendments to assist countries in their negotiations.

In parallel with the IHR amendments process, governments are also negotiating the drafting of an WHO instrument on pandemic prevention, preparedness and response, also referred to as a pandemic accord. Governments will meet from 27 February-3 March 2023 to consider the zero draft of the accord.

Dr Bloomfield said the two processes are complementary, as they are both guided by the imperative of making the world safer from communicable diseases and ensuring equitable responses to public health threats. “The efforts to update the International Health Regulations and draft a pandemic accord share a number of common themes, including the importance of equity in access to health, collaboration and capacity building,” he said. "It is important that there is consistency and alignment across the two processes.”

WHO Member States issued the International Sanitary Regulations in 1951, the precursor to the IHR, which came into being in 2005. The IHR are an instrument of international law that is legally-binding on 196 State Parties, including the 194 WHO Member States. The IHR create rights and obligations for countries, including the requirement to report to WHO public health events with risk of international spread. They also outline the criteria to determine if a particular event constitutes a public health emergency of international concern, WHO’s highest level of alarm under the IHR, which in turn triggers specific response actions for countries to prevent the further spread of the epidemics and reduce their impact on population health and societies at large.


A new era in the fight against measles and rubella
22 February 2023

Joint Statement:
American Red Cross
Bill & Melinda Gates Foundation
Gavi, the Vaccine Alliance
US Centers for Disease Control
United Nations Foundation
UNICEF
WHO

The Measles Initiative was formed in 2001 to establish a global partnership to coordinate efforts to prevent child deaths and morbidity caused by the highly contagious measles virus. In 2012, the founding partners -- American Red Cross, U.S. Centers for Disease Control and Prevention, the United Nations Foundation, UNICEF and the World Health Organization (WHO) – agreed to include rubella elimination under a new name, the Measles and Rubella Initiative (M&RI).

Huge strides have been made since then. The Initiative has helped deliver measles vaccines to children worldwide, contributing to saving over 56 million lives globally since its formation and invested more than US$1.2 billion in measles and rubella control activities, in partnership with Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation (BMGF).

The impact of these investments is significant. From 2000 to 2021, the annual number of estimated measles deaths decreased 83 per cent, from 761,000 to 128,000. While much progress has been made, the goal is to collaborate with countries and partners to achieve the Immunization Agenda 2030 (IA2030) target to save another 50 million lives through access to essential vaccines by the end of 2030, with measles immunization contributing a large percentage.

Towards that end, all founding partners adopted the Measles and Rubella Strategic Framework 2030, which is fully aligned with IA2030, an ambitious global strategy to maximize the lifesaving impact of vaccines. M&RI then began a consultative process to fully integrate the strategy, coordination and action with IA2030 strategy and partnership processes.

As a result of that process, the newly revitalized M&RI partnership will now be called the IA2030 Measles & Rubella Partnership (M&RP). The transition began on 1 January 2023 and has now been formalized.

Building on years of previous work together, the membership of the IA2030 M&RP will include the original five founders and has expanded to include Gavi and BMGF as core partners.

The transition comes at a time when the world has seen the worst continued backsliding in global immunization coverage in 30 years, largely on account of the COVID-19 pandemic and related disruptions. It is opportune as we need to work more closely than ever before to address the nearly 40 per cent increase in the number of unvaccinated children globally.
IA2030 is in its early years, and we are among the first initiatives to transition to IA2030 management. We hope our success will serve as a precedent for other disease-specific initiatives in the coming years. This transition is a step forward to overcome current challenges and ensure all children, everywhere, are protected against measles, rubella, and other vaccine-preventable diseases.

---

‘Science thrives best through international collaboration’ – Jeremy Farrar on ten years at Wellcome

Opinion
Author - Jeremy Farrar (2013-2023)
24 February 2023  Wellcome Trust

It is remarkable to look back on the role of science in enabling extraordinary advances in global health over the last decade – science that Wellcome has supported with researchers and partners around the world. Though the challenges become ever greater and more urgent, I am optimistic that we are living in an era of significant and long-enduring innovation.

Ebola vaccine showed science at its best

I joined Wellcome as Director in 2013, following almost 18 years in Viet Nam researching infectious diseases. I lived and worked through avian flu, SARS-1, epidemics of drug-resistant typhoid and the emergence of HIV. I witnessed first-hand the effects of diseases such as dengue, TB and malaria on local communities. The world had yet to see the shocking impacts of Ebola in West Africa, Zika in South America, and SARS-CoV-2 everywhere.

At the time, Wellcome’s commitment to cutting-edge discovery research – and major activities like the Wellcome Sanger Institute, Francis Crick Institute and Wellcome’s Africa and Asia Programmes – had already led to breakthroughs in the human genome, neuroscience, social sciences and much more. Since then, our ambitions and horizons have grown at a breathtaking scale that even I could not have dared to dream.

There are countless moments where I am proud of Wellcome’s contribution to progress. Our response to the heart-breaking west African Ebola epidemic of 2014-16 stands out. The international community initially responded far too slowly and the epidemic spread across the region, devastating communities – the effects are still felt today. But progress was made with the development of the critically important Ebola vaccine.

This was an example of science at its best. Not so much because of the astonishing achievement of creating that vaccine, but because communities dared to ask: ‘what if?’. What if, during a crisis, we carried out the research needed to progress promising, life-saving science?

There was an appreciation for community ownership, the social sciences and the underlying trust to conduct research in a rapidly developing epidemic, to bring it to an end faster and save lives. This is a position that Guinea, Sierra Leone and Liberia along with partners in the region, WHO, Norway and Wellcome strongly advocated for, put funding behind and implemented.
Not all the lessons the world needed to heed on infectious disease were learnt from that epidemic, but the effective vaccine and treatment studies have saved thousands of lives since. This success is testament to local communities, health workers, researchers and industry.

I can also confidently say that this led to a transformational change to how we approach any disease outbreak, not just Ebola. It led to the creation of **CEPI**, which Wellcome proudly co-founded in 2016 and the set-up of the **WHO R&D Blueprint**. It led to a much quicker response including vaccination in subsequent Ebola epidemics in the Democratic Republic of Congo, and a much faster response to the Covid-19 pandemic in the form of the **RECOVERY** and **Solidarity trials**, which provided the evidence on what vaccines and treatments work and what did not.

By keeping patients and communities at the centre and daring to be bold and ambitious, we can make a meaningful change to health.

**Wellcome’s resource and role**

Thanks to our world-class investments team, Wellcome’s endowment has grown from £15 billion when I joined to £38 billion today, allowing us to more than double the amount we spend annually on research. Over the next ten years to 2033, **Wellcome is committed to spending £16 billion** supporting outstanding science.

Philanthropy cannot and should not replace the role of government or become the establishment. But Wellcome has the resource to initiate change as well as the independence and transparency that can be harnessed to push boundaries where others may not be able to.

It is this outlook that helped us refresh our strategy. We’re now better placed to support discovery, clinical and public health research that will transform our understanding of health, wellbeing and life itself. And we’re supporting science to solve the global health challenges of our changing climate, infectious disease outbreaks and mental health problems through dedicated programmes.

**A vision for the future**

The biggest advances to improve health are rarely, if ever, lone events or strokes of luck. Building on years of painstaking work, scientific success is only possible through iteration and learning. Science thrives best through international collaboration. We live in a highly connected world and we must look beyond our own borders, working together to benefit as many lives as possible. We all owe it to ourselves and to future generations to break down barriers.

It has been a unique honour and great pleasure to lead Wellcome for the last decade and I leave taking with me enormous pride in what we have achieved together.

The mission to improve health has never been more focused in the hands of the amazing teams that make Wellcome what it is today.

**Paul Schreier, Wellcome’s Chief Operating Officer, has been appointed interim Chief Executive Officer**, with effect from 25 February 2023. Jeremy Farrar will take up the position of Chief Scientist of the World Health Organization later this year.
**PHEIC**

**Coronavirus [COVID-19] - WHO**

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**

Last update: 17 Feb 2023

- **Confirmed cases**: 757,264,511
- **Confirmed deaths**: 6,850,594
- **Vaccine doses administered**: 13,223,135,400

**Weekly epidemiological update on COVID-19 - 15 February 2023**

*Overview*

Globally, nearly 5.3 million new cases and over 48,000 deaths were reported in the last 28 days (23 January to 19 February 2023), a decrease of 89% and 62%, respectively, compared to the previous 28 days. As of 19 February 2023, over 757 million confirmed cases and over 6.8 million deaths have been reported globally.

*Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 19 February 2023***

---

**Our World in Data**

**Coronavirus (COVID-19) Vaccinations**  [Accessed 25 Feb 2023]

- 69.7% of the world population has received at least one dose of a COVID-19 vaccine.
- 13.31 billion doses have been administered globally, and 1.05 million are now administered each day.
- 27.7% of people in low-income countries have received at least one dose.
**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessioned 25 Feb 2023**

An overview of information collected from publicly announced bilateral and multilateral supply agreements

| **55** | vaccines approved for use by at least one national regulatory authority |
| **$2–$120** | reported vaccine price range per dose |
| **1.89bn** | doses shipped through COVAX to 146 countries |
| **62K** | Oxygen concentrators delivered to 113 countries |
| **11** | vaccines in WHO’s Emergency Use Listing |
| **17.8bn** | doses secured globally |
| **60K** | novel oral antiviral therapeutic treatments arrived in 10 countries |
| **67** | Pressure Swing Adsorption (PSA) plants delivered to 25 countries |

---

**Global Dashboard on COVID-19 Vaccine Equity**
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

See also visualization on Vaccine Access and Vaccine Affordability

---

**COVID-19 Global Targets and Progress Tracker** – IMF

*This tracker was last updated on May 5 2022. We have archived the information and will no longer provide updates.*

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries
Bar chart is ordered by total number of doses pledged. Donor charts are ordered by proportion of pledged donations shipped.

United States
China
Germany
France
Spain
United Kingdom
Italy
Australia
Japan
Canada

Country Category:
Top 10 Donating Countries

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
COVID Vaccines – OCHA:: HDX

**COVID-19 Data Explorer: Global Humanitarian Operations**

**COVID-19 Vaccine Roll-out**

**Feb 25, 2023** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 125M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.3B

- Number of Countries: 28
- COVAX Allocations Round 4-9 (Number of Doses): 170M
- COVAX Delivered (Number of Doses): 390M
- Other Delivered (Number of Doses): 430M
- Total Delivered (Number of Doses): 830M
- Total Administered (Number of Doses): 590M

**U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**

*News*

*No new digest content identified.*

**FDA**

*Press Announcements*

February 24, 2023 - FDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses

**FDA VRBPAC**
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency [EMA]

*News & Press Releases*

*News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023 (new)*

European Centre for Disease Prevention and Control


*News/Updates/Reports [Selected]*

*Weekly COVID-19 country overview*

Epidemiological update - 23 Feb 2023

*Earthquakes in Türkiye and Syria: infectious diseases expected to be a concern in two to four weeks*

News - 20 Feb 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

[https://africacdc.org/covid-19-vaccination/](https://africacdc.org/covid-19-vaccination/)

*(Last Update: February 2, 2023)*
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China

National Medical Products Administration – PRC [to 25 Feb 2023]
http://english.nmpa.gov.cn/
Spread of COVID-19 epidemic in China basically ended, expert says
2023-02-24
The spread of the COVID-19 epidemic has basically ended in China, though it is not completely over, a senior health expert said on Thursday.
Liang Wannian, head of the National Health Commission’s expert panel on COVID-19 control, said the "decisive victory" in COVID-19 epidemic control, announced at a recent meeting of the Standing Committee of the Political Bureau of the Communist Party of China Central Committee, means that the country has withstood the impact and test of the recent outbreak, with its people achieving herd immunity.

Although COVID-19 remains an international health emergency, China has set an example of a highly populous nation successfully pulling through a pandemic, he said at a news conference. Liang said the decisive victory is the result of the power of China's political system, as the CPC and Chinese government have always prioritized people and the saving of lives, which is the fundamental principle of the nation's epidemic response.

Moreover, the country's political system can ensure that different departments and regions can work together, with governments, enterprises and individuals assuming their responsibilities and realizing synergy, he said.

The mobilization and participation of the public have also been crucial, and the Chinese people have shown a high degree of altruism, unity and dedication in the fight against COVID, he said.

In addition, disease control, public health and medical workers have made notable contributions to winning the fight, and the country has given full play to the role of technology in its epidemic control efforts — from the research and development of vaccines, drugs and testing equipment to the use of big data and artificial intelligence in the tracing and management of close contacts, Liang said. He added that unity, grassroots officials, traditional Chinese medicine and good communication all played major roles in securing the victory.

Yang Feng, an official with the National Administration of Disease Prevention and Control, said that with concerted efforts from the whole country, China's COVID-19 response has made a smooth transition in a relatively short time since November, with more than 200 million people receiving medical treatment and nearly 800,000 patients with severe cases receiving proper treatment. The country's COVID-19 death rate remains the world's lowest, and there was no resurgence of cases during the Spring Festival travel rush, he added.

While the nation's epidemic situation is improving, COVID-19 is still spreading worldwide, and the virus is still mutating. Authorities should continue to implement epidemic control measures and people should safeguard themselves with good health habits to maintain the hard-won success, he added.

Chang Zhaorui, a research fellow at the Chinese Center for Disease Control and Prevention, said there have been seven cases of the XBB.1.5 Omicron subvariant reported in China since Jan 8.

While the new variant is highly transmissible and has become the dominant one in some Western countries, a major outbreak in China is unlikely, given the fact that the country has just gone through a major outbreak, she said.

**China steadily enters new phase of COVID response: spokesperson**

2023-02-24
BEIJING -- **China has steadily entered a new phase of COVID-19 prevention and control, which was downgraded under the management of Class B infectious diseases**, a National Health Commission (NHC) spokesperson said Thursday.

China’s overall COVID-19 response situation is improving, with sporadic COVID-19 cases reported in parts of the country, said spokesperson Mi Feng at a press conference held by the State Council joint COVID-19 prevention and control mechanism.

China has been optimizing COVID-19 prevention and control measures based on the evolving situation over the past more than three years and has succeeded in preventing the widespread prevalence of more virulent and fatal variants, Mi added.

Liang Wannian, head of the COVID-19 response expert panel under the NHC, said at the press conference that **the country has withstood the challenge posed by the latest wave of COVID-19 infections and established sound community immunity, adding that the wave can be said to be basically over.**

As the global COVID-19 pandemic is ongoing, China will further improve the Class B management measures, Mi said, adding that the country will enhance its epidemic surveillance and regular warning capacity, ensure COVID-19 prevention and control at places such as nursing homes and schools, and accelerate COVID-19 vaccination.

According to Yang Feng, an official with the disease prevention and control bureau under the NHC, the country will continue to improve its online direct reporting system for infectious diseases, and will carry out law-enforcement inspections for the reporting of information concerning such diseases.

More than 241.68 million people aged over 60 have been fully vaccinated against COVID-19 so far, accounting for 96.1 percent of the population of that age group, Yang told the press conference.

---

**PHEIC**

Mpox

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

*Last Situation Report:*

**Multi-country outbreak of mpox, External situation report #16 - 16 February 2023**

---

**PHEIC**

Polio
Polio this week as of 22 February 2023 - GPEI

Headlines
:: nOPV2 rollout: Approximately 585 million doses of nOPV2 have been administered across 27 countries under its WHO Emergency Use Listing (EUL) to date. An additional 14 countries have met the requirements for nOPV2 use in the event of an outbreak. Visit the nOPV2 web page for more information.
:: “We believe that it is possible to achieve the national and global immunization targets including eradication and elimination goals. Progress in meeting immunization targets, we believe, is a driver for equitable health outcomes for children, mothers and the population as a whole,” – Dr Julius Maada Bio, President of Sierra Leone. Read more...

Summary of new polioviruses this week:
- Afghanistan: two WPV1 positive environmental samples
- Algeria: two cVDPV2 positive environmental samples
- DRC: four cVDPV2 cases
- Madagascar: one cVDPV1 case and eight positive environmental samples
- Mozambique: two cVDPV1 cases
- Yemen: one cVDPV2 case and five positive environmental samples

UN OCHA – Current Emergencies
Current Corporate Emergencies

Afghanistan
Editor’s Note:
We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Türkiye/Syria Earthquakes
No new digest content identified.

Ukraine
Last Updated: 10 Feb 2023

WHO & Regional Offices [to 25 Feb 2023]
https://www.who.int/news
Selected News/Announcements/Statements
25 February 2023  Statement
Governments hold first detailed discussions on proposed amendments to the International Health Regulations (2005)

24 February 2023  News release
Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season

22 February 2023  Statement
A new era in the fight against measles and rubella

21 February 2023  Departmental news
Multidisciplinary Technical Advisory Group established to advise WHO on local production and technology transfer of health products

20 February 2023  Departmental news
Updated good practice statement on the use of variant-containing COVID-19 vaccines

::::

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: Vaccines help battle cholera outbreak in Malawi  22 February 2023
...Since the onset of the cholera outbreak in Malawi in March 2022, World Health Organization has supported the country to access 4.9 million doses of oral cholera vaccines from the International Coordinating Group—the body that manages emergency supplies of vaccines—with funding from Gavi, the Vaccine Alliance. To date, vaccines have been deployed in 21 out of Malawi’s 29 districts. In May and June 2022, 1.95 million doses were administered during a campaign in nine of the most affected districts, in the country’s Southern region. A second batch of 2.9 million doses arrived in October and WHO together with UNICEF supported a vaccination campaign in 14 more districts. In Nkhata Bay District, the number of new cases decreased from 381 in October 2022 to only 43 in December 2022. For both campaigns, only one dose was administered instead of two, due to the global shortage in oral cholera vaccines...
:: Zimbabwe tackles measles outbreak through intensive vaccination campaigns  20 February 2023
:: African leaders call for urgent action to revitalize routine immunization  19 February 2023

WHO Region of the Americas  PAHO
:: PAHO provides training to Caribbean laboratory technicians in cholera detection and molecular characterization
  Bridgetown, Barbados, 22 February 2023 (PAHO) – Efforts to strengthen cholera surveillance in the region continued last week with a three-day training, organized by the Pan American Health Organization (PAHO) and delivered by the Costa Rican Institute of Research and Training in Nutrition and Health (INCIENS). The virtual training, which took...

WHO South-East Asia Region  SEARO
No new digest content identified.
WHO European Region EURO

:: 24 February 2023  News release
More than 100 000 people reached with key health interventions at Ukraine’s frontlines

:: 23 February 2023  News release
The crucial role of cultural mediators in Romania's Ukrainian refugee response

:: 23 February 2023  News release
Strengthening surgical skills contributes to emergency preparedness in the Republic of Moldova

WHO Western Pacific Region

No new digest content identified.

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

25 February 2023 | Marburg virus disease - Equatorial Guinea

24 February 2023 | Cholera - Mozambique

New WHO Publications

https://www.who.int/publications/i

Selected Titles

24 February 2023
Target product profile for readers of rapid diagnostic tests

23 February 2023

22 February 2023
HIV self-testing at workplaces: approaches to implementation and sustainable financing

21 February 2023
Considerations for integrating COVID-19 vaccination into immunization programmes and primary health...

21 February 2023
WHO Strategic and Technical Advisory Group for Antimicrobial Resistance(STAG-AMR)

20 February 2023
Good practice statement on the use of variant-containing COVID-19 vaccines
Supporting the routine use of evidence during the policy-making process: a WHO checklist

Overview

This WHO checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WHO’s Thirteenth General Programme of Work 2019–2023 (GPW13). This checklist was developed by the WHO Secretariat of Evidence-Informed Policy Network (EVIPNet) to assist its Member countries in institutionalizing EIPM. Government agencies (i.e. the staff of the Ministry of Health), knowledge intermediaries and researchers focused on strengthening EIPM will find in this checklist some key steps and tools to help their work. While the health sector is a key target group for EVIPNet, this tool can be applied by stakeholders from different social sectors.

CDC/ACIP [U.S.] [to 25 Feb 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
No new digest content identified.

ACIP Meetings

ACIP Meeting: February 22-23, 2023
Final Agenda
ACIP Presentation Slides: February 22-24, 2023 Meeting

MMWR Weekly
February 24, 2023 / No. 8
PDF of this issue
- Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023
- Notes from the Field: Aircraft Wastewater Surveillance for Early Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City, August–September 2022
- Notes from the Field: Epidemiologic Characteristics of SARS-CoV-2 Recombinant Variant XBB.1.5 — New York City, November 1, 2022–January 4, 2023

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries.

2/24/23
COVID Data Tracker Recent Updates - 2023-02-23 - Updated booster dose data for the total population and the population younger than age 18 years were added to the Vaccination Equity page.

2/23/23
Notes from the Field: Epidemiologic Characteristics of SARS-CoV-2 Recombinant Variant XBB.1.5 — New York City, November 1, 2022–January 4, 2023

2/23/23
Notes from the Field: Aircraft Wastewater Surveillance for Early Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City, August–September 2022

Africa CDC  [to 25 Feb 2023]
http://www.africacdc.org/
News
Africa CDC Urgent Support to Avert COVID-19 Vaccines Expiry in Africa
23 February 2023

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China  [to 25 Feb 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.
[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]

National Medical Products Administration – PRC  [to 25 Feb 2023]
http://english.nmpa.gov.cn/
Spread of COVID-19 epidemic in China basically ended, expert says
2023-02-24
The spread of the COVID-19 epidemic has basically ended in China, though it is not completely over, a senior health expert said on Thursday.

China steadily enters new phase of COVID response: spokesperson
2023-02-24
China has steadily entered a new phase of COVID-19 prevention and control, which was downgraded under the management of Class B infectious diseases, a National Health Commission spokesperson said Thursday.
China CDC Weekly Reports: Current Volume (5)
2023-02-24 / No. 8

View PDF of this issue

- Preplanned Studies: Asymptomatic Norovirus Infection Among Children in Kindergartens and Primary Schools — Beijing Municipality, China, 2021
- Preplanned Studies: A Questionnaire Survey on Extrapulmonary Tuberculosis Control and Prevention — China, 2021
- Vital Surveillances: Dynamic Changes of ORF1ab and N Gene Ct Values in COVID-19 Omicron Inpatients of Different Age Groups — Beijing Municipality, China, November–December 2022
- HTML (1290) PDF 341KB(2)

Organization Announcements

Paul G. Allen Frontiers Group [to 25 Feb 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation [to 25 Feb 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 25 Feb 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 25 Feb 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 25 Feb 2023]
https://centerforvaccineethicsandpolicy.net/

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 25 Feb 2023]
http://cepi.net/
Latest News
No new digest content identified.

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 25 Feb 2023]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 25 Feb 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP** [to 25 Feb 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

**Emory Vaccine Center** [to 25 Feb 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

**European Vaccine Initiative** [to 25 Feb 2023]
http://www.euvaccine.eu/
Latest News, Events
News, Events
No new digest content identified.

**Evidence Aid** [to 25 Feb 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

**Fondation Merieux** [to 25 Feb 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

**Gavi** [to 25 Feb 2023]
https://www.gavi.org/
News Releases
No new digest content identified.

**GHIT Fund** [to 25 Feb 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

**Global Fund** [to 25 Feb 2023]
News & Stories
21 February 2023
**Global Fund Announces Additional Emergency Funding in Ukraine After One Year of War**

The Global Fund to Fight AIDS, Tuberculosis and Malaria has approved an additional US$10.32 million in emergency funding to maintain essential HIV and tuberculosis (TB) services in Ukraine as this week marks one year since Russia launched a full-scal...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 25 Feb 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

**Hilleman Laboratories** [to 25 Feb 2023]
HHMI - Howard Hughes Medical Institute [to 25 Feb 2023]
http://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 25 Feb 2023]
http://www.humanvaccinesproject.org/
News
Selected Statements, Press Releases, Research
No new digest content identified.

IAVI [to 25 Feb 2023]
http://www.iavi.org/
Latest News
FEATURES
February 22, 2023
The Netherlands renews their support to IAVI for the development of new HIV prevention technologies
... The Ministry will award IAVI €21 million over the next five years as part of the Product Development Partnership IV Fund.

ICRC [to 015 Oct 2022]
What’s New [Selected]
Russia-Ukraine international armed conflict: The Red Cross and Red Crescent response one year on
Download the full report here
The Russia-Ukraine international armed conflict has had a devastating impact on the lives of millions of people.
23-02-2023 | Report

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

**IFRC**  [to 25 Feb 2023]
*Press Releases [Selected]*
Press release
23/02/2023
**Ukraine: IFRC warns of psychological wounds adding cruel layer of pain one year on**

Press release
23/02/2023
**Pacific: Urgent call for collective action to reduce the impact of climate change and**

**Institut Pasteur**  [to 25 Feb 2023]
*Press Documents*
No new digest content identified.

**ISC / International Science Council**  [to 25 Feb 2023]
https://council.science/current/
*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

Latest Updates
News
**One year on: Statements, offers of assistance and resources on the current war in Ukraine**
24.02.2023

**International Union of Immunological Societies (UIUS)**
https://iuis.org/
*News/Events [Selected]*
No new digest content identified.

**IVAC**  [to 25 Feb 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
*Updates; Events*
No new digest content identified.

**IVI**  [to 25 Feb 2023]
http://www.ivi.int/
*IVI News & Announcements*
No new digest content identified.
Johns Hopkins Center for Health Security  [to 25 Feb 2023]
https://www.centerforhealthsecurity.org/news:center-news/
Center News  [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 25 Feb 2023]
http://www.msf.org/
Latest [Selected Announcements]
Sudan
Bringing healthcare back to conflict-stricken communities in Sudan
Voices from the Field 24 Feb 2023

Türkiye and Syria earthquake response
MSF remains committed to providing care in all areas of Syria
Press Release 22 Feb 2023

Democratic Republic of Congo
Measles: The never-ending fight against one of the world’s most contagious diseases
[measles]...
Project Update 21 Feb 2023

Türkiye and Syria earthquake response
MSF calls for urgent assistance to people in northwest Syria
Press Release 19 Feb 2023

National Academy of Medicine - USA  [to 25 Feb 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA  [to 25 Feb 2023]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS  [to 25 Feb 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH  [to 25 Feb 2023]
**News Releases**

**Long-acting antiretroviral therapy suppresses HIV among people with unstable housing, mental illnesses, substance use disorders**

February 21, 2023 — NIH-supported study demonstrates injectable ART may improve outcomes in underserved patients

**PATH** [to 25 Feb 2023]
https://www.path.org/media-center/

**Press Releases**

No new digest content identified.

**Rockefeller Foundation** [to 25 Feb 2023]
https://www.rockefellerfoundation.org/

**Selected Reports/Press Releases**

Feb 21 2023

**Press Releases**

**CIDRAP Releases Coronavirus Vaccines R&D Roadmap to Advance a New Global Strategy for Broadly Protective Vaccines**

Plan Would Accelerate a New Approach to Coronavirus Vaccines Research and Development to Protect Against Covid-19 Variants and Future Pandemic Threats From New Coronaviruses

**Sabin Vaccine Institute** [to 25 Feb 2023]
https://www.sabin.org/press/

**Latest News & Press Releases**

No new digest content identified.

**UNAIDS** [to 25 Feb 2023]
http://www.unaids.org/en

**Selected Press Releases/Reports/Statements**

24 February 2023

**Upholding UNAIDS responsibility to communities**

23 February 2023

**Thailand partners develop community-led HIV care curriculum**

**UNICEF** [to 25 Feb 2023]
https://www.unicef.org/media/press-releases

**Remarks**

24 February 2023

**UNICEF Geneva Palais briefing note on the situation of earthquake-affected children and families in Türkiye**
GENEVA, 24 February 2023 - "I have just returned from Türkiye, where I saw first-hand some of the devastation left by the powerful earthquakes in south-east Türkiye and Syria. "I was in Kahramanmaras, one of the 11 most affected provinces. Seventeen days after the earthquakes reduced buildings to rubble, thousands of families are still huddled in...

Press release
21 February 2023

**War in Ukraine pushes generation of children to the brink, warns UNICEF**

KYIV/NEW YORK, 21 February 2023 – Almost one year since the escalation of the war in Ukraine on February 24, 2022, a generation of children has experienced 12 months of violence, fear, loss and tragedy. There is not a single aspect of children’s lives that the conflict has not impacted, with children killed, injured, forced from their homes,...
March 2023 webinar reminder; Have you registered for the next “Current Issues in Vaccines” webinar yet? On March 15, 2023, at noon ET, Dr. Offit will discuss: *The Future of COVID-19 Vaccines*

**Wellcome Trust** [to 25 Feb 2023]
https://wellcome.ac.uk/news
*News. Opinion, Reports*
*Opinion*
Author - Jeremy Farrar (2013-2023)
‘Science thrives best through international collaboration’ – Jeremy Farrar on ten years at *Wellcome*
24 February 2023

*Work in progress*
Author - Martin Smith
**Meet the team experimenting with creative approaches to Wellcome’s policy work**
22 February 2023

**The Wistar Institute** [to 25 Feb 2023]
*Media*
No new digest content identified.

**WFPHA: World Federation of Public Health Associations** [to 25 Feb 2023]
https://www.wfpha.org/
*Latest News - Blog*
No new digest content identified.

**World Medical Association [WMA]** [to 25 Feb 2023]
*Press Releases*
No new digest content identified.

**World Organisation for Animal Health (OIE)** [to 25 Feb 2023]
https://www.oie.int/en/
*Press Releases, Statements*
*News*
The sixth meeting of the Global Leaders Group discusses the global response to antimicrobial resistance
Published on 21 February 2023
A key focus of the meeting was to begin GLG planning for the second United Nations General Assembly High-level Meeting on AMR, scheduled for 2024, at which the GLG will press for bold and specific commitments from member states to tackle the growing threats of antimicrobial resist
Statement 21 February 2023
Second meeting of the Working Group on Amendments to the International Health Regulations (2005) (WGIHR)

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases
**ReSViNet 2023 data reinforce AstraZeneca’s commitment to help prevent Respiratory Syncytial Virus in infants**
21 February 2023
:: Beyfortus continues to demonstrate consistent protection against RSV disease through the RSV season
:: New Canadian analysis demonstrates Synagis to be highly cost-effective in 29-35 weeks gestational age infants

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
24 February 2023
**Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster**

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinagen
Recent News - No new digest announcements identified
Clover Biopharmaceuticals - China
News
Feb 20, 2023
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
23 February 2023
ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1
ViiV Healthcare announced positive 12-month findings from the SOLAR study.

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases
February 22, 2023
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

February 22, 2023
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

February 21, 2023
Merck Provides Update on Phase 3 MOVE-AHEAD Trial Evaluating LAGEVRIÖ™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19

Moderna
Press Releases
22 February, 2023
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted
Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

Nanogen
News  - No new digest announcements identified

Novartis
News  - No new digest announcements identified

Novavax
Press Releases  - No new digest announcements identified

Pfizer
Recent Press Releases
02.24.2023
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster

02.22.2023
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

02.21.2023
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases
February 21, 2023
Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants

Serum Institute of India
NEWS & ANNOUNCEMENTS  - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News  - No new digest announcements identified

Sinovac
Press Releases
Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Child Abuse and Neglect

Child abuse is so common that it has become a subspecialty in pediatrics. Indeed, children are 40 times more likely to be confirmed victims of abuse or neglect than to be diagnosed with cancer. “Upstream” obligations to help prevent abuse and neglect of children accompany clinicians’ “downstream” obligations as mandatory reporters, first responders, secondary illness and injury documentarians, and gatherers of forensic evidence. Since clinicians are also key communicators with children, perpetrators, parents, and colleagues during or following clinical encounters, how well they promote short- and long-term healing among persons who are or were victims of child abuse or neglect is often a function of how well they express trauma-informed care values in practice. This theme issue also considers how clinicians should best promote healing among persons, including themselves, who struggle to manage their own psychological and emotional secondary trauma responses when taking care of children who are abused and neglected.

American Journal of Infection Control
February 2023  Volume 51  Issue 2  p121-240
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
February 2023  Volume 64  Issue 2  p149-304
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
February 2023  113(2)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 108 (2023): Issue 2 (Feb 2023)
https://www.ajtmh.org/view/journals/tpmd/108/2/tpmd.108.issue-2.xml
[Reviewed earlier]

Annals of Internal Medicine
February 2023  Volume 176, Issue 2
The Dark Side of Rapid Reviews: A Retreat From Systematic Approaches and the Need for Clear Expectations and Reporting
Zachary Munn, PhD, Danielle Pollock, PhD, Timothy Hugh Barker, PhD, Jennifer Stone, PhD, ... et al.
Pages: 266–267

Artificial Intelligence – An International Journal
Volume 315  February 2023
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Reviewed earlier)

BMJ Global Health
February 2023 - Volume 8 - 2
https://gh.bmj.com/content/8/2
[Reviewed earlier]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Reviewed earlier)
Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study
Electronic informed consent (eIC) may offer various advantages compared to paper-based informed consent. However, the regulatory and legal landscape related to eIC provides a diffuse image. By drawing from the...
Authors: Evelien De Sutter, Pascal Borry, Isabelle Huys and Liese Barbier
Citation: BMC Health Services Research 2023 23:181
Content type: Research Published on: 21 February 2023

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Reviewed earlier)
Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials
Tuberculosis (TB) remains a leading cause of death worldwide, with 98% of cases occurring in low- and middle-income countries (LMICs). The only vaccine licenced for the prevention of TB has limited protection ...
Possibility of mpox viral transmission and control from high-risk to the general population: a modeling study
Mpx is an emerging infectious disease that is now a global hazard. The strategies for preventing and controlling mpx should be further investigated in terms of transmission characteristics, infection risk am...
Authors: Shiting Yang, Xiaohao Guo, Zeyu Zhao, Buasiyamu Abudunaibi, Yunkang Zhao, Jia Rui, Yao Wang, Wentao Song, Hongjie Wei and Tianmu Chen
Citation: BMC Infectious Diseases 2023 23:119
Content type: Research Published on: 24 February 2023

Evaluation of the impact of COVID-19 in people coinfected with HIV and/or tuberculosis in low-income countries: study protocol for mixed methods research in Burkina Faso
An issue of particular concern is the impact of the 2019 novel coronavirus (2019 nCOV) on the people coinfected with the Human Immuno-deficiency Virus (HIV) and/or tuberculosis (TB). Unfortunately, this intera...
Authors: Cheick Ahmed Ouattara, Armel G Poda, Ziemlé Clément Méda, Yacouba Sawadogo, Odilon Kabore, Emile Birba, Adama Sourabié, Jacques Zoungrana, Isidore Tiandiogo Traore, Ibrahim Sangaré, Awa Ymba, Sylvain Godreuil and Abdoul-Salam Ouedraogo
Citation: BMC Infectious Diseases 2023 23:108
Content type: Study Protocol Published on: 22 February 2023

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 25 Feb 2023)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmd/content
(Accessed 25 Feb 2023)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 25 Feb 2023)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 Feb 2023)
The CONFIDENT study protocol: a randomized controlled trial comparing two methods to increase long-term care worker confidence in the COVID-19 vaccines

Clinical and real-world effectiveness data for the COVID-19 vaccines have shown that they are the best defense in preventing severe illness and death throughout the pandemic. However, in the US, some groups re...

Authors: Gabrielle Stevens, Lisa C. Johnson, Catherine H. Saunders, Peter Schmidt, Ailyn Sierpe, Rachael P. Thomeer, N. Ruth Little, Matthew Cantrell, Renata W. Yen, Jacqueline A. Pogue, Timothy Holahan, Danielle C. Schubbe, Rachel C. Forcino, Branden Fillbrook, Rowena Sheppard, Celeste Wooten...

Citation: BMC Public Health 2023 23:384
Content type: Study Protocol Published on: 23 February 2023

BMC Research Notes
http://www.biomedcentral.com/bmcresearchnotes/content
(Accessed 25 Feb 2023)
[No new digest content identified]

BMJ Evidence-Based Medicine
February 2023 - Volume 28 - 1
https://ebm.bmj.com/content/28/1
[Reviewed earlier]

BMJ Open
January 2023 - Volume 13 - 1
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(2); 2023 Feb 1
https://www.ncbi.nlm.nih.gov/pmc/issues/427334/
[Reviewed earlier]

Cell
Feb 16, 2023 Volume 186 Issue 4 p663-892
https://www.cell.com/cell/current
Featured Article
Hallmarks of neurodegenerative diseases
David M. Wilson III, Mark R. Cookson, Ludo Van Den Bosch, Henrik Zetterberg, David M. Holtzman, Ilse Dewachter
Open Access
Summary
Decades of research have identified genetic factors and biochemical pathways involved in neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks of NDD:
pathological protein aggregation, synaptic and neuronal network dysfunction, aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA defects, inflammation, and neuronal cell death. We describe the hallmarks, their biomarkers, and their interactions as a framework to study NDDs using a holistic approach. The framework can serve as a basis for defining pathogenic mechanisms, categorizing different NDDs based on their primary hallmarks, stratifying patients within a specific NDD, and designing multi-targeted, personalized therapies to effectively halt NDDs.

Child Care, Health and Development
Volume 49, Issue 2  Pages: 211-406  March 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 113, Issue 2  Pages: 197-445  February 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
January 2023  Volume 45  Issue 1  p1-88
http://www.clinicaltherapeutics.com/current
Editorial
Encapsulating the Full Impact of Emerging Drugs on Pharma, Patients, and the Global Market
Jill L. Maron
Published online: January 16, 2023

Clinical Trials
Volume 20 Issue 1, February 2023
https://journals.sagepub.com/toc/ctja/20/1
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 25 Feb 2023]
Ensuring equity in mental health and psychosocial support during the COVID-19 pandemic and beyond
Authors: Andrea Armijos, Annie G. Bonz, Felicity L. Brown, Danielle Charlet, Flora Cohen, M. Claire Greene, Sabrina Hermosilla, Leah E. James and Karine Le Roch
Content type: Research 19 February 2023

Contemporary Clinical Trials
Volume 125  February 2023
The CRISPR Journal
Volume 6, Issue 1 / February 2023
https://www.liebertpub.com/toc/crispr/5/7
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Opinion in Infectious Diseases
February 2023 - Volume 36 - Issue 1
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 4 Pages: 181-299 December 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 1, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 1  January 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
Disasters
Volume 47, Issue 1  Pages: 1-244  January 2023
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 24  Issue 2  6 February 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 1—January 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 42  March 2023
Research article  Open access
A statistical framework for tracking the time-varying superspreading potential of COVID-19 epidemic
Zihao Guo, Shi Zhao, Shui Shan Lee, Chi Tim Hung, ... Eng Kiong Yeoh
Article 100670

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 1  Pages: 1-38  January–February 2023
https://onlinelibrary.wiley.com/toc/25782363/current
Ancillary-care obligations - Evaluating public policy interventions
[Reviewed earlier]

Ethics & International Affairs
Winter 2022 (36.4)  December 21, 2022
Ethics, Medicine and Public Health
Volume 26, February 2023
Review article  Abstract only
Caregivers’ engagement in pharmaceutical assessment and development: A systematic literature review
M.L. Longacre, M. Frieler, M. Haefele
Article 100867

The European Journal of Public Health
Volume 33, Issue 1, February 2023
https://academic.oup.com/eurpub/issue/33/1
Health services research
The architecture of the European Union’s pandemic preparedness and response policy framework
Dimitri Eerens, Rok Hrzic, Timo Clemens
European Journal of Public Health, Volume 33, Issue 1, February 2023, Pages 42–48,
https://doi.org/10.1093/eurpub/ckac154

Migration
Women's health in migrant populations: a qualitative study in France
Lisa Ouanhnon, Pauline Astruc, Anne Freyens, Pierre Mesthé, Karine Pariente ...
European Journal of Public Health, Volume 33, Issue 1, February 2023, Pages 99–105,
https://doi.org/10.1093/eurpub/ckac133

Expert Review of Vaccines
Vol 22 (1) 2023  Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 102, Number 1, January/February 2023
https://www.foreignaffairs.com/issues/2023/102/1
[No new digest content identified]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]
Genetics in Medicines
Volume 25, Issue 2  February 2023

Editorial

**Rare disease therapeutics: The future of medical genetics in a changing landscape**
Christopher D. Connolly, Shane C. Quinonez, Elizabeth G. Ames
Article 100339

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 25 Feb 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
December 2022 | Volume 10 | Number 6
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 25 Feb 2023]
[No new digest content identified]

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 Feb 2023]

**Socio-economic, governance and health indicators shaping antimicrobial resistance: an ecological analysis of 30 European countries**
Authors: Andrea Maugeri, Martina Barchitta, Federico Puglisi and Antonella Agodi
Content type: Research 24 February 2023
Previous evidence shows that antibiotic use and antimicrobial resistance (AMR) spread are not always perfectly correlated within and between countries. We conducted an ecological analysis to evaluate how demographic, economic, governance, health, and freedom characteristics of 30 European countries contribute to antibiotic consumption and AMR.
**Immunity**
Feb 14, 2023  Volume 56  Issue 2  p225-458
https://www.cell.com/immunity/current
[New issue; No digest content identified]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 25 Feb 2023]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjourn.com/content
[Accessed 25 Feb 2023]
[No new digest content identified]

**International Health**
Volume 15, Issue 1, January 2023
https://academic.oup.com/inthealth/issue/15/1
[Reviewed earlier]

**International Human Rights Law Review**
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol. 10 No. 1 (2023): January 2023
https://www.ijcmph.com/index.php/ijcmph/issue/view/96
[Reviewed earlier]

**International Journal of Epidemiology**
Volume 51, Issue 6, December 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**
Vol. 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
*Special Issue: Children, young people and their international human right to healthcare*
Research Letter

Dissemination of the Results of Pediatric Clinical Trials Funded by the US National Institutes of Health

Chris A. Rees, MD, MPH; Claire Narang, BS; Adrianna Westbrook, MPH; et al.

This study examines practices related to trial registration and results submission in ClinicalTrials.gov and publication of pediatric clinical trials funded by the National Institutes of Health.

Discussion

Among NIH-funded pediatric trials, lack of prospective trial registration and failure to submit trial results to ClinicalTrials.gov was common, consistent with findings from studies examining registration and results dissemination across broad groups of trials.4,5 In addition, almost half of pediatric trials did not have results published 4 years after completion of NIH funding.

Study limitations include that not all trial publications may have been identified and that the analyses relied on publicly available data that could not be verified. Additionally, certain trials may have been published beyond the follow-up period examined.

The NIH recently announced plans to increase enforcement activities for trial registration and reporting and to verify adherence to these requirements prior to issuing subsequent awards to NIH-funded investigators.6 While there is an ethical obligation for timely dissemination of all research involving human participants, this responsibility warrants particular consideration when trials are supported by public funds and enroll pediatric patients.

JAMA Health Forum

February 2023, Vol 4, No. 2
https://jamanetwork.com/journals/jama-health-forum/issue

JAMA Pediatrics

February 2023, Vol 177, No. 2, Pages 107-216
https://jamanetwork.com/journals/jamapediatrics/currentissue

JBI Evidence Synthesis

February 2023 - Volume 21 - Issue 2
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

Journal of Adolescent Health
Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 48, issue 1, February 2023
https://link.springer.com/journal/10900/volumes-and-issues/48-1

Original Paper
Rural-Urban Disparities in HPV Vaccination Coverage Among Adolescents in the Central Part of the State of Illinois, USA
Authors (first, second and last of 7)
Eric Adjei Boakye, Yuri Fedorovich, Mary A Gerend
Published: 06 September 2022
Pages: 24 - 29

Predictors of COVID-19 Vaccine Uptake in Teachers: An On-line Survey in Greece
Authors (first, second and last of 4)
Ioannis Moisoglou, Christina Passali, Petros Galanis
Content type: Original Paper
Published: 15 October 2022
Pages: 59 - 66

Knowledge and Attitudes of Physicians and Nurses in Turkey Regarding Human Papillomavirus Vaccination of Their Children
Authors (first, second and last of 4)
Filiz Tubaş, Ramazan DULKADİR, Erdal ÜNLÜ
Content type: Original Paper
Published: 28 October 2022
Pages: 99 - 103

COVID-19 Vaccination Rates and Vaccine Hesitancy Among Spanish-Speaking Free Clinic Patients
Authors (first, second and last of 7)
Alexandra Scheiber, Teresa B. Prinster, Kathleen Wyne
Content type: Original Paper
Published: 31 October 2022
Pages: 127 - 135

Journal of Development Economics
Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2023 - Volume 77 - 3
https://jech.bmj.com/content/77/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 4 Pages: 315-424 December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 3, 2022
http://www.tandfonline.com/toc/rjge20/current
[New issue; No digest content identified]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 1, February 2023
https://muse.jhu.edu/issue/49033
Table of Contents
[New issue; No digest content identified]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023 _ Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]
Evaluation of vaccine storage and distribution practices in rural healthcare facilities in Kenya

Vaccines require cold chain storage conditions, and good distribution practices throughout the supply chain to maintain their quality and potency. However, in the last mile of the vaccines supply chain, these ...

Authors: Dennis Kipkoech Sinnei, Peter Ndirangu Karimi, Shital Mahindra Maru, Stephen Karengera and Thomas Bizimana

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:25
Content type: Research Published on: 21 February 2023
The Lancet
Feb 25, 2023  Volume 401  Number 10377  p617-704, e18
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Russia’s invasion of Ukraine: an attack on health
The Lancet

Articles
Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis
Yang Pan, et al/

Series
One Health
How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach

Tieble Traore, et al

Summary
The COVID-19 pandemic has exposed faults in the way we assess preparedness and response capacities for public health emergencies. Existing frameworks are limited in scope, and do not sufficiently consider complex social, economic, political, regulatory, and ecological factors. One Health, through its focus on the links among humans, animals, and ecosystems, is a valuable approach through which existing assessment frameworks can be analysed and new ways forward proposed. Although in the past few years advances have been made in assessment tools such as the International Health Regulations Joint External Evaluation, a rapid and radical increase in ambition is required. To sufficiently account for the range of complex systems in which health emergencies occur, assessments should consider how problems are defined across stakeholders and the wider sociopolitical environments in which structures and institutions operate. Current frameworks do little to consider anthropogenic factors in disease emergence or address the full array of health security hazards across the social–ecological system. A complex and interdependent set of challenges threaten human, animal, and ecosystem health, and we cannot afford to overlook important contextual factors, or the determinants of these shared threats. Health security assessment frameworks should therefore ensure that the process undertaken to prioritise and build capacity adheres to core One Health principles and that interventions and outcomes are assessed in terms of added value, trade-offs, and cobenefits across human, animal, and environmental health systems.

Global and regional governance of One Health and implications for global health security

Azza Elnaiem, et al.

Summary
The apparent failure of global health security to prevent or prepare for the COVID-19 pandemic has highlighted the need for closer cooperation between human, animal (domestic and wildlife), and environmental health sectors. However, the many institutions, processes, regulatory frameworks, and legal instruments with direct and indirect roles in the global governance of One Health have led to a fragmented, global, multilateral health security architecture. We explore four challenges: first, the sectoral, professional, and institutional silos and tensions existing between human, animal, and environmental health; second, the challenge that the international legal system, state sovereignty, and existing legal instruments pose for the governance of One Health; third, the power dynamics and asymmetry in power between countries represented in multilateral institutions and their impact on priority setting; and finally, the current financing mechanisms that predominantly focus on response to crises, and the chronic underinvestment for epidemic and emergency prevention, mitigation, and preparedness activities. We illustrate the global and regional dimensions to these four challenges and how they relate to national needs and priorities through three case studies on compulsory licensing, the governance of water resources in the Lake Chad Basin, and the desert locust infestation in east Africa. Finally, we propose 12 recommendations for the global community to address these challenges. Despite its broad and holistic agenda, One Health continues to be dominated by human and domestic animal health experts. Substantial efforts should be made to address the social–ecological drivers of health emergencies including outbreaks of emerging, re-emerging, and endemic infectious diseases. These drivers include climate change, biodiversity loss, and land-use change, and therefore require effective and enforceable legislation, investment, capacity building, and integration of other sectors and professionals beyond health.
Nature
Volume 614 Issue 7949, 23 February 2023
https://www.nature.com/nature/volumes/614/issues/7949
Editorial  22 Feb 2023
Rebuilding Ukrainian science can’t wait — here’s how to start
International support has rightly focused on researchers who have been forced to flee. Ukraine’s devastated research infrastructure needs assistance, too.

Perspective  22 Feb 2023
CAR immune cells: design principles, resistance and the next generation
This Perspective reviews recent developments in the design and use of chimeric antigen receptors in treatments for cancers and other diseases.
Louai Labanieh, Crystal L. Mackall

Article  04 Jan 2023
Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19
Immune responses to influenza vaccination are affected by previous mild COVID-19 in a sex-dimorphic manner.
Rachel Sparks, William W. Lau, John S. Tsang

Nature Biotechnology
Volume 41 Issue 2, February 2023
https://www.nature.com/nbt/volumes/41/issues/2
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 25 Feb 2023)
[No new digest content identified]

Nature Genetics
Volume 55 Issue 2, February 2023
https://www.nature.com/ng/volumes/55/issues/2
[Reviewed earlier]

Nature Human Behaviour
The association between vaccination status identification and societal polarization

Henkel et al. show that people's identification with their COVID-19 vaccination status is associated with polarization in attitudes, behaviours and acceptance of vaccination policies.

Luca Henkel, Philipp Sprengholz, Robert Böhm

Nature Medicine

Comorbidities, multimorbidity and COVID-19

This Review discusses the effect of comorbidities and multimorbidity on the three mechanistically distinct phases of COVID-19, evaluating the evidence in the context of confounding factors and our evolving understanding of the disease.

Clark D. Russell, Nazir I. Lone, J. Kenneth Baillie

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population

An analysis of sera samples collected between January and July of 2022 in Hong Kong shows that the effectiveness of both the BNT162b2 and CoronaVac COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 variant infection waned rapidly after the third and fourth doses.

Jonathan J. Lau, Samuel M. S. Cheng, Joseph T. Wu

A survey of COVID-19 vaccine acceptance across 23 countries in 2022

In the third annual iteration of a survey assessing vaccine confidence in 23 high-income, middle-income and low-income countries, although results were heterogeneous across countries, overall willingness to accept a COVID-19 vaccine was found to have increased.

Jeffrey V. Lazarus, Katarzyna Wyka, Ayman El-Mohandes

Nature Reviews Drug Discovery

Nature Reviews Genetics

Nature Reviews Immunology
http://www.plosntds.org/
(Accessed 25 Feb 2023)
[PloS journal websites not responding at inquiry for recent articles]

**PLoS One**
http://www.plosone.org/
[Acessed 25 Feb 2023]
[PloS journal websites not responding at inquiry for recent articles]

**PLoS Pathogens**
http://journals.plos.org/plospathogens/
[Acessed 25 Feb 2023]
[PloS journal websites not responding at inquiry for recent articles]

**PNAS - Proceedings of the National Academy of Sciences of the United States**
February 21, 2023  vol. 120 no. 8
https://www.pnas.org/toc/pnas/120/8
[New issue; No digest content identified]

**PNAS Nexus**
Volume 2, Issue 2, February 2023
IN PROGRESS
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]

**Prehospital & Disaster Medicine**
Volume 38 - Issue 1 - February 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

**Preventive Medicine**
Volume 167  February 2023
[New issue; No digest content identified]

**Proceedings of the Royal Society B**
22 February 2023  Volume 290  Issue 1993
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]
Public Health
Volume 214  Pages 1-180 (January 2023)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 3, November 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 1, January/February 2023
https://journals.sagepub.com/toc/phrg/138/1
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 3, February 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 1, January 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 25 Feb 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
21 Feb 2023
Historical evolution of World Health Organization guidelines on antimicrobial resistance
Special report | Spanish |

Risk Analysis
Volume 43, Issue 1  Pages: 1-201  January 2023
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus with Evolving Perspectives
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 25 Feb 2023]
[No new digest content identified]

Science
Volume 379 | Issue 6634 | 24 Feb 2023
https://www.science.org/toc/science/current
Editorial
Science for humanity
BY Gilda A. Barabino
23 Feb 2023: 73

Science and Engineering Ethics
Volume 29, issue 1, February 2023
https://link.springer.com/journal/11948/volumes-and-issues/29-1
[Reviewed earlier]

Science Translational Medicine
Volume 15 | Issue 684 | 22 Feb 2023
https://www.science.org/toc/stm/current
Report
Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals
BY Stijn P. Andeweg, et al. [....] RIVM COVID-19 Molecular epidemiology group
22 Feb 2023
Open Access
SARS-CoV-2 genomic epidemiology shows increased breakthrough, but not reinfection rates, by the Beta, Gamma, or Delta variants compared with Alpha.

Social Science & Medicine
Volume 318 | February 2023
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 25 Feb 2023]
Travel Medicine and Infectious Diseases
Volume 51  January–February 2023
[Reviewed earlier]
Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 06 Jan 2023]
[Filter: All articles]
Selected Research

Burden of lower respiratory tract infections preventable by adult immunization with 15- and 20-valent pneumococcal conjugate vaccines in the United States
Joseph Lewnard, Vennis Hong, Katia Bruxvoort, Lindsay R Grant, Luis Jodar, Alejandro Cane, Adriano Arguedas, Magdalena Pomichowski, Bradford Gessner, Sara Tartof
medRxiv 2023.02.23.23286380; doi: https://doi.org/10.1101/2023.02.23.23286380

Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study
George Qian, Thibaut Jombart, W John Edmunds
medRxiv 2023.02.22.23286294; doi: https://doi.org/10.1101/2023.02.22.23286294

Examining the governance arrangements for healthcare worker COVID-19 protection in Kenya: A Scoping Review
Jacob Kazungu, Nancy N Kagwanja, Huihui Wang, Jane Chuma, Kenneth Munge
medRxiv 2023.02.22.23286303; doi: https://doi.org/10.1101/2023.02.22.23286303
Multilevel determinants of Covid-19 vaccine hesitancy and undervaccination among marginalized populations in the United States: A scoping review
Peter A. Newman, Thabani Nyoni, Kate Allan, Sophia Fantus, Duy Dinh, Suchon Tepjan, Luke Reid, Adrian Guta
medRxiv 2023.02.23.23286342; doi: https://doi.org/10.1101/2023.02.23.23286342

Vaccine-induced correlate of protection against fatal COVID-19 in the old and frail during waves of neutralization resistant variants of concern.
medRxiv 2023.02.16.23286009; doi: https://doi.org/10.1101/2023.02.16.23286009

Generative AI as a Tool for Environmental Health Research Translation
Lauren B. Anderson, Dhiraj Kanneganti, Mary Bentley Houk, Rochelle H. Holm, Ted Smith

A Systematic Review on Medical Oxygen Ecosystem: Current State and Recent Advancements
Ehtashamul Haque, Khondaker A. Mamun
medRxiv 2022.10.23.22281394; doi: https://doi.org/10.1101/2022.10.23.22281394 Revision

Cholera past and future in Nigeria: are the Global Task Force on Cholera Control’s 2030 targets achievable?
Gina E C Charnley, Sebastian Yennan, Chinwe Ochu, Ilan Kelman, Katy A M Gaythorpe, Kris A Murray
medRxiv 2022.12.06.22283154; doi: https://doi.org/10.1101/2022.12.06.22283154 Revision

Modelling Vaccination Strategies for the Control of Marburg Virus Disease Outbreaks
George Y Qian, W John Edmunds, Daniel G Bausch, Thibaut Jombart
medRxiv 2022.06.17.22276538; doi: https://doi.org/10.1101/2022.06.17.22276538 Revision

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 06 Jan 2023]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
No new digest content identified.

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
Research Article Open Access
SARS-CoV-2 Omicron variant of concern in the Seychelles: Introduction and spread [version 1; peer review: awaiting peer review]
John Mwita Morobe, At al.

The emergence of the Omicron variant of concern in late 2021 led to a resurgence of SARS-CoV-2 infections globally. By September 2022, Seychelles had experienced two major surges of SARS-CoV-2 infections driven by the Omicron variant. Here, we examine the genomic epidemiology of Omicron in the Seychelles between November 2021 and September 2022.

* * * *

**Think Tanks**

**Brookings** [to 25 Feb 2023]
http://www.brookings.edu/
Latest Research [Selected] Technology & Innovation
All Research [Selected] CGD NOTES
No new digest content identified.

**Center for Global Development** [to 25 Feb 2023]
https://www.cgdev.org/
All Research [Selected] CGD NOTES
No new digest content identified.

**Chatham House** [to 25 Feb 2023]
https://www.chathamhouse.org/
Selected Analysis, Comment, Events
No new digest content identified.

**CSIS** [to 25 Feb 2023]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

**Kaiser Family Foundation** [to 25 Feb 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

**McKinsey Global Institute**
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.
**ODI [Overseas Development Institute]** [to 25 Feb 2023]
*Publications [Selected]*

**Strengthening inclusive social protection systems for displaced children and their families**
20 February 2023
*Briefing/policy papers*

**Pew Research Center** [to 25 Feb 2023]
https://www.pewresearch.org/
*Latest Publications [Selected]*

**The Future of Human Agency**
Experts are split about how much control people will retain over essential decision-making as digital systems and artificial intelligence spread. They agree that powerful corporate and government authorities will expand the role of AI in people’s daily lives in useful ways. But, many worry these systems will diminish individuals’ ability to control their choices.

**Rand** [to 25 Feb 2023]
https://www.rand.org/pubs.html
*Published Research [Selected]*

**The relationship between research spending and research performance: A cross-country and in-depth study**
This study investigates the relationship between spending and research performance through an econometric analysis and also investigates potential nonlinearities in the relationship between spending and performance through a series of case studies.
Feb 22, 2023
Joachim Krapels, Marco Hafner, Anne Kirtley, Enora Robin, Paulina Pankowska, Louise Lepetit, Jacopo Bellasio, Susan Guthrie

**Journal Article**

**International Humanitarian Narratives of Disasters, Crises and Indigeneity**
Narratives are a means of making sense of disasters and crises. We identify and characterise narratives in humanitarian communications involving Indigenous Peoples by conducting a narrative analysis of humanitarian communications.
Feb 22, 2023
Anuszka Maton-Mosurska, Aaron Clark-Ginsberg, James D. Ford, Susannah M. Sallu, Katy Davis
Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

*:*:*:*
*:*:*:*
*:*:*:*
*:*:*:*

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

*:*:*:*

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.